OS was retrospectively compared between advanced NSCLC patients with sensitive EGFR mutations who began first-line systemic therapy before and after gefitinib approval in Japan (January 1999–July 2001 and July 2002–December 2004, respectively) [31]. Here, EGFR is linked to non-small cell lung carcinoma.